Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan E Bates

Showing results (131-140 of 293) with videos related to

Pageof 30
Sort By:
The Oncologist|October 22, 2025
Cancer Interception During Treatment: Using Growth Kinetics to Create a Continuous Variable for Assessing Disease ResponseMengxi Zhou, Antonion T Fojo, Lawrence H Schwartz, et al.
Journal of Molecular Graphics & Modelling|October 10, 2006
Towards understanding the mechanism of action of the multidrug resistance-linked half-ABC transporter ABCG2: a molecular modeling studyYong-Fu Li, Orsolya Polgar, Masaki Okada, et al.
Cancer Research|September 4, 2014
Therapies with diverse mechanisms of action kill cells by a similar exponential process in advanced cancersKrastan B Blagoev, Julia Wilkerson, Wilfred D Stein, et al.
Cardiovascular Drugs and Therapy|May 11, 2005
Effect of a histone deacetylase inhibitor on human cardiac massYukitaka Shizukuda, Richard L Piekarz, Susan E Bates, et al.
Cancer Letters|July 2, 2005
Localization of the ABCG2 mitoxantrone resistance-associated protein in normal tissuesPatricia A Fetsch, Andrea Abati, Thomas Litman, et al.
Molecular Cancer Therapeutics|October 15, 2009
Escape from hsa-miR-519c enables drug-resistant cells to maintain high expression of ABCG2Kenneth K W To, Robert W Robey, Turid Knutsen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 15, 2006
Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176)Robert W Robey, Zhirong Zhan, Richard L Piekarz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2015
Advancing Clinical Trials to Streamline Drug DevelopmentSusan E Bates, Donald A Berry, Sanjeeve Balasubramaniam, et al.
Cancer Research|February 20, 2004
Pheophorbide a is a specific probe for ABCG2 function and inhibitionRobert W Robey, Kenneth Steadman, Orsolya Polgar, et al.
International Journal of Cancer|February 22, 2002
Impact of BCRP/MXR, MRP1 and MDR1/P-Glycoprotein on thermoresistant variants of atypical and classical multidrug resistant cancer cellsUlrike Stein, Hermann Lage, Andreas Jordan, et al.
Pageof 30

Showing results (131-140 of 293) with videos related to

Sort By:
Pageof 30
The Oncologist|October 22, 2025
Cancer Interception During Treatment: Using Growth Kinetics to Create a Continuous Variable for Assessing Disease ResponseMengxi Zhou, Antonion T Fojo, Lawrence H Schwartz, et al.
Journal of Molecular Graphics & Modelling|October 10, 2006
Towards understanding the mechanism of action of the multidrug resistance-linked half-ABC transporter ABCG2: a molecular modeling studyYong-Fu Li, Orsolya Polgar, Masaki Okada, et al.
Cancer Research|September 4, 2014
Therapies with diverse mechanisms of action kill cells by a similar exponential process in advanced cancersKrastan B Blagoev, Julia Wilkerson, Wilfred D Stein, et al.
Cardiovascular Drugs and Therapy|May 11, 2005
Effect of a histone deacetylase inhibitor on human cardiac massYukitaka Shizukuda, Richard L Piekarz, Susan E Bates, et al.
Cancer Letters|July 2, 2005
Localization of the ABCG2 mitoxantrone resistance-associated protein in normal tissuesPatricia A Fetsch, Andrea Abati, Thomas Litman, et al.
Molecular Cancer Therapeutics|October 15, 2009
Escape from hsa-miR-519c enables drug-resistant cells to maintain high expression of ABCG2Kenneth K W To, Robert W Robey, Turid Knutsen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 15, 2006
Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176)Robert W Robey, Zhirong Zhan, Richard L Piekarz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2015
Advancing Clinical Trials to Streamline Drug DevelopmentSusan E Bates, Donald A Berry, Sanjeeve Balasubramaniam, et al.
Cancer Research|February 20, 2004
Pheophorbide a is a specific probe for ABCG2 function and inhibitionRobert W Robey, Kenneth Steadman, Orsolya Polgar, et al.
International Journal of Cancer|February 22, 2002
Impact of BCRP/MXR, MRP1 and MDR1/P-Glycoprotein on thermoresistant variants of atypical and classical multidrug resistant cancer cellsUlrike Stein, Hermann Lage, Andreas Jordan, et al.
Pageof 30